New Two-Drug attack on advanced stomach cancer enters Mid-Stage testing
NCT ID NCT06947291
Summary
This study is testing whether combining an experimental targeted drug (glumetinib) with an existing chemotherapy (docetaxel) can help control advanced stomach, gastroesophageal, and other solid tumors that have a specific genetic feature (MET overexpression/amplification). It aims to find a safe and effective dose for the combination and see how well it shrinks tumors. The trial is recruiting 350 adults with these advanced cancers who have not been treated with certain prior medications.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED GASTRIC CANCER/GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AND OTHER SOLID TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Zhejiang Cancer Hospital
RECRUITINGHangzhou, Zhejiang, China
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.